Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study
European Respiratory Journal · 2025
DOI: 10.1183/13993003.02435-2024 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Marcus A Mall und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Aminophenols. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in children aged 6–11 years with cystic fibrosis (CF) heterozygous for F508del and a minimal function CF transmembrane conductance regulator ( CFTR ) variant ( F /MF genotypes) in a 24-week, placebo-controlled trial. We conducted a 96-week open-label extension study for children who completed the 24-week parent study.
Methods
In this phase 3b extension study, dosing was based on weight and age, with children weighing
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- German Center for Child and Adolescent Health (DZKJ), partner site, Berlin, Germany.
- German Center for Lung Research (DZL), associated partner site Berlin, Berlin, Germany.
- Co-lead authors.
- Queensland Children's Hospital, University of Queensland, South Brisbane, Australia.
- National Institute for Health Research, Southampton Respiratory Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
ORCID-Profile: Marcus A Mall, Claire E Wainwright, Anna-Maria Dittrich
Förderung
- Vertex Pharmaceuticals
Zitieren
APA
Mall, M. A., Wainwright, C. E., Legg, J., Chilvers, M., Gartner, S., Dittrich, A. M., Stehling, F., Conner, S., Grant, S., Suresh, N., Weinstock, T. G., Davies, J. C., & VX20-445-119 Study Group (2025). Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study. European Respiratory Journal. https://doi.org/10.1183/13993003.02435-2024
Vancouver
Mall MA, Wainwright CE, Legg J, Chilvers M, Gartner S, Dittrich AM, et al. Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study. European Respiratory Journal. 2025. doi:10.1183/13993003.02435-2024
BibTeX
@article{Mall2025,
author = {Mall, Marcus A and Wainwright, Claire E and Legg, Julian and Chilvers, Mark and Gartner, Sylvia and Dittrich, Anna-Maria and Stehling, Florian and Conner, Sarah and Grant, Sebastian and Suresh, Nina and Weinstock, Tanya G and Davies, Jane C and VX20-445-119 Study Group, VX20-445-119 Study Group},
title = {Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.02435-2024}
}
EUVIMED